logo-loader
RNS
ConvaTec Group PLC

Non-Executive Director appointment

RNS Number : 3076S
Convatec Group PLC
27 August 2026
 

27 August 2026

Convatec Group Plc
("Convatec" or the "Company")

Non-Executive Director appointment

 

London, UK, 27 August 2026 - Convatec today announces the appointment of Dr Jens Viebke as a Non-Executive Director, effective immediately. He also joins the Remuneration Committee.

 

Jens brings more than three decades of experience developing and commercialising healthcare technologies across the life sciences and medical technology sectors, including leadership roles at Getinge, GE Healthcare Life Sciences and Amersham Biosciences. His experience spans R&D, strategy, product development, commercial operations and general management, and will complement the Board's expertise in innovation, product development and global medtech markets, supporting Convatec's continued focus on innovation-driven growth as it executes its Accelerate strategy.

 

Jens is currently a Non-Executive Director of Bone Support AB, Sedana Medical AB and Stille AB. He is also Chairman of Epista Life Science.

 

Dr John McAdam CBE, Chair, Convatec, says: "We are delighted to welcome Jens to the Board. He brings extensive international MedTech experience, having held leadership roles across research and development, product innovation, strategy and business management. His deep understanding of the innovation lifecycle, from research through to commercialisation, together with his experience of operating in highly regulated healthcare markets, will be a valuable addition to the Board as we continue to execute our Accelerate strategy and deliver sustainable growth."

 

Dr Jens Viebke, Non-Executive Director, Convatec, says: "I am very pleased to be joining John, Jonny and the Convatec team. The company has a strong heritage of innovation, particularly clear from its success over the past six years, a clear purpose and leading positions in attractive markets. I look forward to playing my part in supporting Convatec to advance its science and innovation agenda, as the company delivers its Accelerate strategy and creates long-term value for patients, customers, colleagues and shareholders."

 

Contact

 

Media: mediarelations@convatec.com
Analysts and investor relations:
 ir@convatec.com        

Company Secretariat: cosec@convatec.com

 

Notes
Biographical information for Dr Viebke can be viewed on the company's website.

 

This announcement is made in accordance with Listing Rule 6.4.6. There is no further information to be disclosed under the requirements of Listing Rule 6.4.8 in relation to Dr Viebke's appointment.

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAAKABDABKDQFB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Holding(s) in Company

1 day, 10 hours ago

Convatec 10-month trading update

1 day, 14 hours ago

Transaction in Own Shares

3 days, 10 hours ago

Transaction in Own Shares

1 week, 3 days ago

Director updates

2 weeks, 2 days ago

Total Voting Rights

2 weeks, 3 days ago

Transaction in Own Shares

2 weeks, 3 days ago

3 min read